ID

33266

Description

Study ID: 107434 Clinical Study ID: NAP107434 Study Title: A randomised, double-blind, double-dummy, placebo controlled, three-way cross-over study to investigate the effect of single oral doses of 100 mg GW273225 (4030W92) and 325 mg LAMICTAL on resting motor threshold in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Study Link: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GW273225 Trade Name: lamictal Study Indication: Bipolar Disorder This form contains informations about any unscheduled blood sampling for pharmakokinetics. It should be filled out at follow up visit. It should be filled out at each visit, if any unscheduled blood samples for pharmacogenetics had been taken. Screening Visit: 28 days prior to first dosing. Treatment Period: The day before dosing, until 48h after dosing. Follow-Up: 14-21 days after last dose

Mots-clés

Versions (3)

1. 03/12/2018 03/12/2018 -
2. 19/12/2018 19/12/2018 -
3. 09/01/2019 09/01/2019 -

Détendeur de droits

GlaxoSmithKline

Téléchargé le

3 décembre 2018

DOI

Pour une demande vous connecter.

Licence